Related Experiment Video

Updated: Aug 7, 2026

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling
07:49

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling

Published on: August 3, 2018

Large- and small-molecule inhibitors of transforming growth factor-beta signaling

Rosemary J Akhurst1

  • 1University of California at San Francisco, P.O. Box 0875, Cancer Research Institute, 2340 Sutter Street, San Francisco, CA 94143-0875, USA. rakhurst@cc.ucsf.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|June 21, 2006
PubMed

Insights

Transforming growth factor-beta (TGF-β) inhibitors show promise in reducing cancer metastasis and improving drug delivery. Clinical trials suggest improved survival rates for glioblastoma patients treated with these novel TGF-β therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Transforming growth factor-beta (TGF-β) signaling pathways are implicated in various cancers.
  • Existing therapeutic strategies aim to inhibit TGF-β at different molecular levels, including synthesis, ligand-receptor interactions, and downstream kinase activity.

Purpose of the Study:

  • To review the development and efficacy of TGF-β inhibitors in preclinical and clinical settings.
  • To explore the potential of TGF-β inhibitors in cancer treatment, focusing on metastasis and drug delivery.
  • To discuss patient variability in response to TGF-β inhibitors based on genetic factors.

Main Methods:

  • Review of preclinical studies evaluating TGF-β inhibitors for anti-metastatic effects and enhanced drug delivery.
  • Analysis of Phase I/II clinical trial data for TGF-β inhibitors in glioblastoma patients.
  • Discussion of factors influencing therapeutic response, including tumor type, cellular targets, and patient-specific genetic variations.

Main Results:

  • Preclinical studies demonstrate TGF-β inhibitors can reduce metastasis and improve cytotoxic drug delivery.
  • Phase I/II clinical trials in glioblastoma patients indicate improved survival rates compared to conventional chemotherapy.
  • Therapeutic targets (cancer cells, stromal cells, immune cells, angiogenesis) may vary across tumor types.

Conclusions:

  • TGF-β inhibitors represent a promising therapeutic strategy for various cancers.
  • Individual patient responses are influenced by germline genetics and tumor somatic mutations, necessitating personalized treatment approaches.
  • Further understanding of these factors will optimize patient selection and minimize adverse effects for TGF-β targeted therapies.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay11:38

Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay

Published on: September 14, 2021

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...